<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Allogeneic hematopoietic stem cell transplantation (HSCT) offers the unique opportunity to replace a diseased hematopoietic or immune system by healthy donor cells </plain></SENT>
<SENT sid="1" pm="."><plain>Proof of principle comes from experimental animal data, from the experience with severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, from observations of patients with concomitant <z:hpo ids='HP_0002960'>autoimmune disease</z:hpo> and from scattered case reports </plain></SENT>
<SENT sid="2" pm="."><plain>Complete remissions have been described as well as failures </plain></SENT>
<SENT sid="3" pm="."><plain>Allogeneic HSCT remains associated with significant morbidity and mortality </plain></SENT>
<SENT sid="4" pm="."><plain>The potential risks might outweight the benefits </plain></SENT>
<SENT sid="5" pm="."><plain>Currently, allogeneic HSCT cannot be recommended in general </plain></SENT>
<SENT sid="6" pm="."><plain>Carefully conducted prospective studies are warranted to define target populations and best technology to be used </plain></SENT>
<SENT sid="7" pm="."><plain>Conditions for such studies have been identified by an international expert panel </plain></SENT>
</text></document>